tiprankstipranks
Edwards Lifesciences (CH:EW)
:EW
Switzerland Market
EW
Edwards Lifesciences
RESEARCH TOOLSreports

Edwards Lifesciences (EW) Stock Forecast & Price Target

2 Followers
See the Price Targets and Ratings of:

EW Analyst Ratings

Strong Buy
17Ratings
Strong Buy
14 Buy
3 Hold
0 Sell
Based on 17 analysts giving stock ratings to
Edwards
Lifesciences
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

EW Stock 12 Month Forecast

Average Price Target

CHF82.69
▲(20.24% Upside)
Based on 17 Wall Street analysts offering 12 month price targets for Edwards Lifesciences in the last 3 months. The average price target is CHF82.69 with a high forecast of CHF88.36 and a low forecast of CHF68.28. The average price target represents a 20.24% change from the last price of CHF68.77.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"67":"CHF67","78":"CHF78","89":"CHF89","72.5":"CHF72.5","83.5":"CHF83.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":88.3634213,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">CHF88.36</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":82.68674090133332,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">CHF82.69</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":68.28082555,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">CHF68.28</span>\n  </div></div>","useHTML":true}}],"tickPositions":[67,72.5,78,83.5,89],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,68.772,70.27903240769231,71.78606481538462,73.29309722307693,74.80012963076923,76.30716203846154,77.81419444615385,79.32122685384616,80.82825926153846,82.33529166923077,83.84232407692308,85.34935648461538,86.85638889230769,{"y":88.3634213,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,68.772,69.84236468471795,70.9127293694359,71.98309405415385,73.0534587388718,74.12382342358974,75.19418810830769,76.26455279302564,77.33491747774359,78.40528216246153,79.47564684717948,80.54601153189743,81.61637621661538,{"y":82.68674090133332,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,68.772,68.73421735000001,68.69643470000001,68.65865205,68.6208694,68.58308675,68.54530410000001,68.50752145,68.4697388,68.43195615,68.39417350000001,68.35639085,68.3186082,{"y":68.28082555,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":68.772,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68.772,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68.772,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68.772,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68.772,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68.772,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68.772,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 49,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68.772,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68.772,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68.772,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68.772,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68.772,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68.772,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price TargetCHF88.36Average Price TargetCHF82.69Lowest Price TargetCHF68.28
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
William Blair Analyst forecast on CH:EW
Brandon Vazquez
William Blair
William Blair
―
Buy
―
Reiterated
08/18/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Brainstorm Cell Therapeutics (Other OTC: BCLI) and Edwards Lifesciences (NYSE: EW)
Citi Analyst forecast on CH:EW
Joanne Wuensch
Citi
Citi
CHF88.36
Buy
28.49%
Upside
Reiterated
08/13/26
Citi Sticks to Their Buy Rating for Edwards Lifesciences (EW)
Canaccord Genuity Analyst forecast on CH:EW
William Plovanic
Canaccord Genuity
Canaccord Genuity
CHF68.28
Hold
-0.71%
Downside
Reiterated
08/03/26
Balanced NTAP Tailwinds and Cautious TMTT Rollout Lead Plovanic to Maintain Hold Rating and Unchanged $85 Price Target on Edwards Lifesciences
J.P. Morgan Analyst forecast on CH:EW
Robbie Marcus
J.P. Morgan
J.P. Morgan
CHF84.35
Buy
22.65%
Upside
Reiterated
07/28/26
J.P. Morgan Sticks to Their Buy Rating for Edwards Lifesciences (EW)
UBS Analyst forecast on CH:EW
Patrick Wood
UBS
UBS
CHF72.3→CHF88.36
Buy
28.49%
Upside
Upgraded
07/28/26
Analysts Offer Insights on Healthcare Companies: Universal Health (NYSE: UHS), Insmed (NASDAQ: INSM) and Edwards Lifesciences (NYSE: EW)
Piper Sandler Analyst forecast on CH:EW
Adam Maeder
Piper Sandler
Piper Sandler
CHF80.33→CHF81.13
Buy
17.98%
Upside
Reiterated
07/24/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Edwards Lifesciences (NYSE: EW), Atricure (NASDAQ: ATRC) and Medpace Holdings (NASDAQ: MEDP)
Oppenheimer Analyst forecast on CH:EW
Suraj Kalia
Oppenheimer
Oppenheimer
―
Hold
―
Reiterated
07/24/26
Analysts Offer Insights on Healthcare Companies: Incyte (NASDAQ: INCY) and Edwards Lifesciences (NYSE: EW)
Truist Financial Analyst forecast on CH:EW
Richard Newitter
Truist Financial
Truist Financial
CHF76.31
Hold
10.97%
Upside
Reiterated
07/24/26
Analysts Are Neutral on These Healthcare Stocks: DENTSPLY SIRONA (XRAY), Edwards Lifesciences (EW)
Leerink Partners Analyst forecast on CH:EW
Mike Kratky
Leerink Partners
Leerink Partners
CHF69.89→CHF81.13
Buy
17.98%
Upside
Upgraded
07/24/26
Edwards Lifesciences upgraded to Outperform from Market Perform at LeerinkEdwards Lifesciences upgraded to Outperform from Market Perform at Leerink
Stifel Nicolaus Analyst forecast on CH:EW
Rick Wise
Stifel Nicolaus
Stifel Nicolaus
CHF88.36
Buy
28.49%
Upside
Reiterated
07/24/26
Stifel Nicolaus Keeps Their Buy Rating on Edwards Lifesciences (EW)
BTIG Analyst forecast on CH:EW
Marie Thibault
BTIG
BTIG
CHF88.36
Buy
28.49%
Upside
Reiterated
07/24/26
Analysts Offer Insights on Healthcare Companies: Edwards Lifesciences (NYSE: EW) and GE Healthcare Technologies Inc (NASDAQ: GEHC)
TD Cowen Analyst forecast on CH:EW
Josh Jennings
TD Cowen
TD Cowen
CHF83.54
Buy
21.48%
Upside
Assigned
07/23/26
Edwards Lifesciences: Buy Rating Reaffirmed as Analyst Lifts Price Target from $85 to $104 on TAVR Momentum and TMTT Catalysts
RBC Capital Analyst forecast on CH:EW
Shagun Singh Chadha
RBC Capital
RBC Capital
CHF88.36
Buy
28.49%
Upside
Reiterated
07/23/26
RBC Capital Keeps Their Buy Rating on Edwards Lifesciences (EW)
Bank of America Securities Analyst forecast on CH:EW
Travis Steed
Bank of America Securities
Bank of America Securities
CHF80.33
Buy
16.81%
Upside
Reiterated
07/21/26
Analysts' Top Healthcare Picks: Edwards Lifesciences (EW), Arcus Biosciences (RCUS)
Mizuho Securities Analyst forecast on CH:EW
Anthony Petrone
Mizuho Securities
Mizuho Securities
CHF80.33→CHF84.35
Buy
22.65%
Upside
Reiterated
07/15/26
Edwards Lifesciences price target raised to $105 from $100 at MizuhoEdwards Lifesciences price target raised to $105 from $100 at Mizuho
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
William Blair Analyst forecast on CH:EW
Brandon Vazquez
William Blair
William Blair
―
Buy
―
Reiterated
08/18/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Brainstorm Cell Therapeutics (Other OTC: BCLI) and Edwards Lifesciences (NYSE: EW)
Citi Analyst forecast on CH:EW
Joanne Wuensch
Citi
Citi
CHF88.36
Buy
28.49%
Upside
Reiterated
08/13/26
Citi Sticks to Their Buy Rating for Edwards Lifesciences (EW)
Canaccord Genuity Analyst forecast on CH:EW
William Plovanic
Canaccord Genuity
Canaccord Genuity
CHF68.28
Hold
-0.71%
Downside
Reiterated
08/03/26
Balanced NTAP Tailwinds and Cautious TMTT Rollout Lead Plovanic to Maintain Hold Rating and Unchanged $85 Price Target on Edwards Lifesciences
J.P. Morgan Analyst forecast on CH:EW
Robbie Marcus
J.P. Morgan
J.P. Morgan
CHF84.35
Buy
22.65%
Upside
Reiterated
07/28/26
J.P. Morgan Sticks to Their Buy Rating for Edwards Lifesciences (EW)
UBS Analyst forecast on CH:EW
Patrick Wood
UBS
UBS
CHF72.3→CHF88.36
Buy
28.49%
Upside
Upgraded
07/28/26
Analysts Offer Insights on Healthcare Companies: Universal Health (NYSE: UHS), Insmed (NASDAQ: INSM) and Edwards Lifesciences (NYSE: EW)
Piper Sandler Analyst forecast on CH:EW
Adam Maeder
Piper Sandler
Piper Sandler
CHF80.33→CHF81.13
Buy
17.98%
Upside
Reiterated
07/24/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Edwards Lifesciences (NYSE: EW), Atricure (NASDAQ: ATRC) and Medpace Holdings (NASDAQ: MEDP)
Oppenheimer Analyst forecast on CH:EW
Suraj Kalia
Oppenheimer
Oppenheimer
―
Hold
―
Reiterated
07/24/26
Analysts Offer Insights on Healthcare Companies: Incyte (NASDAQ: INCY) and Edwards Lifesciences (NYSE: EW)
Truist Financial Analyst forecast on CH:EW
Richard Newitter
Truist Financial
Truist Financial
CHF76.31
Hold
10.97%
Upside
Reiterated
07/24/26
Analysts Are Neutral on These Healthcare Stocks: DENTSPLY SIRONA (XRAY), Edwards Lifesciences (EW)
Leerink Partners Analyst forecast on CH:EW
Mike Kratky
Leerink Partners
Leerink Partners
CHF69.89→CHF81.13
Buy
17.98%
Upside
Upgraded
07/24/26
Edwards Lifesciences upgraded to Outperform from Market Perform at LeerinkEdwards Lifesciences upgraded to Outperform from Market Perform at Leerink
Stifel Nicolaus Analyst forecast on CH:EW
Rick Wise
Stifel Nicolaus
Stifel Nicolaus
CHF88.36
Buy
28.49%
Upside
Reiterated
07/24/26
Stifel Nicolaus Keeps Their Buy Rating on Edwards Lifesciences (EW)
BTIG Analyst forecast on CH:EW
Marie Thibault
BTIG
BTIG
CHF88.36
Buy
28.49%
Upside
Reiterated
07/24/26
Analysts Offer Insights on Healthcare Companies: Edwards Lifesciences (NYSE: EW) and GE Healthcare Technologies Inc (NASDAQ: GEHC)
TD Cowen Analyst forecast on CH:EW
Josh Jennings
TD Cowen
TD Cowen
CHF83.54
Buy
21.48%
Upside
Assigned
07/23/26
Edwards Lifesciences: Buy Rating Reaffirmed as Analyst Lifts Price Target from $85 to $104 on TAVR Momentum and TMTT Catalysts
RBC Capital Analyst forecast on CH:EW
Shagun Singh Chadha
RBC Capital
RBC Capital
CHF88.36
Buy
28.49%
Upside
Reiterated
07/23/26
RBC Capital Keeps Their Buy Rating on Edwards Lifesciences (EW)
Bank of America Securities Analyst forecast on CH:EW
Travis Steed
Bank of America Securities
Bank of America Securities
CHF80.33
Buy
16.81%
Upside
Reiterated
07/21/26
Analysts' Top Healthcare Picks: Edwards Lifesciences (EW), Arcus Biosciences (RCUS)
Mizuho Securities Analyst forecast on CH:EW
Anthony Petrone
Mizuho Securities
Mizuho Securities
CHF80.33→CHF84.35
Buy
22.65%
Upside
Reiterated
07/15/26
Edwards Lifesciences price target raised to $105 from $100 at MizuhoEdwards Lifesciences price target raised to $105 from $100 at Mizuho
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
ODTXOdyssey Therapeutics, Inc.
AVBPArriVent BioPharma, Inc.
BTSGBrightSpring Health Services, Inc.
GPCRStructure Therapeutics, Inc. Sponsored ADR
AMLXAmylyx Pharmaceuticals Inc
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Edwards Lifesciences

3 Months
Adam MaederPiper Sandler
Success Rate
18/28 ratings generated profit
64%
Average Return
+1.60%
Copying Adam Maeder's trades and holding each position for 3 Months would result in 64.29% of your transactions generating a profit, with an average return of +1.60% per trade.
1 Year
Adam MaederPiper Sandler
Success Rate
23/28 ratings generated profit
82%
Average Return
+9.41%
Copying Adam Maeder's trades and holding each position for 1 Year would result in 82.14% of your transactions generating a profit, with an average return of +9.41% per trade.
2 Years
Larry BiegelsenWells Fargo
Success Rate
15/21 ratings generated profit
71%
Average Return
+11.56%
Copying Larry Biegelsen's trades and holding each position for 2 Years would result in 71.43% of your transactions generating a profit, with an average return of +11.56% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

EW Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
0
0
0
0
0
Buy
35
30
40
39
34
Hold
11
3
5
6
7
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
46
33
45
45
41
In the current month, EW has received 34 Buy Ratings, 7 Hold Ratings, and 0 Sell Ratings. EW average Analyst price target in the past 3 months is 82.69.
Each month's total comprises the sum of three months' worth of ratings.

EW Financial Forecast

EW Earnings Forecast

Next quarter’s earnings estimate for EW is CHF0.59 with a range of CHF0.58 to CHF0.62. The previous quarter’s EPS was CHF0.63. EW beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year EW has Performed in-line its overall industry.
Next quarter’s earnings estimate for EW is CHF0.59 with a range of CHF0.58 to CHF0.62. The previous quarter’s EPS was CHF0.63. EW beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year EW has Performed in-line its overall industry.

EW Sales Forecast

Next quarter’s sales forecast for EW is CHF1.35B with a range of CHF1.33B to CHF1.38B. The previous quarter’s sales results were CHF1.40B. EW beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year EW has Performed in-line its overall industry.
Next quarter’s sales forecast for EW is CHF1.35B with a range of CHF1.33B to CHF1.38B. The previous quarter’s sales results were CHF1.40B. EW beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year EW has Performed in-line its overall industry.

EW Stock Forecast FAQ

What is CH:EW’s average 12-month price target, according to analysts?
Based on analyst ratings, Edwards Lifesciences’s 12-month average price target is 82.69.
    What is CH:EW’s upside potential, based on the analysts’ average price target?
    Edwards Lifesciences has 20.24% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Edwards Lifesciences a Buy, Sell or Hold?
          Edwards Lifesciences has a consensus rating of Strong Buy, which is based on 14 buy ratings, 3 hold ratings and 0 sell ratings.
            What is Edwards Lifesciences’s share price target?
            The average share price target for Edwards Lifesciences is 82.69. This is based on 17 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is CHF88.36 ,and the lowest forecast is CHF68.28. The average share price target represents 20.24% Increase from the current price of CHF68.77.
              What do analysts say about Edwards Lifesciences?
              Edwards Lifesciences’s analyst rating consensus is a Strong Buy. This is based on the ratings of 17 Wall Streets Analysts.
                How can I buy shares of Edwards Lifesciences?
                To buy shares of CH:EW, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.